CC

Caxton Corporation Portfolio holdings

AUM $4.02M
1-Year Est. Return 256.08%
This Fund
S&P 500
This Quarter Est. Return
1 Year Est. Return
+256.08%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$4.02M
AUM Growth
-$255K
Cap. Flow
Cap. Flow %
Top 10 Hldgs %
Holding
12
New
Increased
Reduced
Closed

Top Buys

1
+$295K
2
+$39.9K
3
+$8.35K

Top Sells

1
+$292K
2
+$210K
3
+$158K
4
SABS icon
SAB Biotherapeutics
SABS
+$39.4K
5
CNTX icon
Context Therapeutics
CNTX
+$27.1K

Sector Composition

1 Healthcare 9.84%
2 Financials 8.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GLD icon
1
SPDR Gold Trust
GLD
$149B
$3.28M 81.5%
7,623
+659
BRK.B icon
2
Berkshire Hathaway Class B
BRK.B
$1.02T
$348K 8.66%
727
+17
KYTX icon
3
Kyverna Therapeutics
KYTX
$480M
$162K 4.03%
18,773
LXEO icon
4
Lexeo Therapeutics
LXEO
$354M
$80K 1.99%
13,943
XFOR icon
5
X4 Pharmaceuticals
XFOR
$381M
$64.2K 1.6%
15,557
IKT icon
6
Inhibikase Therapeutics
IKT
$224M
$47.8K 1.19%
28,453
ALXO icon
7
ALX Oncology
ALXO
$240M
$42K 1.04%
+20,946
CMPX icon
8
Compass Therapeutics
CMPX
$375M
– –
-29,495
CNTX icon
9
Context Therapeutics
CNTX
$222M
– –
-18,403
DFTX
10
Definium Therapeutics
DFTX
$2.49B
– –
-15,688
SABS icon
11
SAB Biotherapeutics
SABS
$266M
– –
-10,527
SYRE icon
12
Spyre Therapeutics
SYRE
$6.01B
– –
-8,919